

Irene Solana López¹, **Juan Antonio Guerra Martínez**, **Diego Malón Giménez**, **Laura Rodríguez Lajusticia**, **Carmen Pantín González**, **Ana Manuela Martín Fernández de Soignie**, **Carlos de Zea Luque**, **Beatriz Losada Vila**, **Nadia Sánchez Baños**, **Fátima Escalona Martín**, **Elia Martínez Moreno**, **David Gutiérrez Abad**, **Ignacio Juez Martel**, **Beatriz Jiménez Munarriz**, **Julia Calzas Rodríguez**

Servicio de Oncología Médica, Hospital Universitario de Fuenlabrada, Camino del Molino N° 2, Madrid, Spain

News and updates in the treatment of localized stage triple-negative breast cancer

Address for correspondence:

Dr. Irene Solana López
 Servicio de Oncología médica, Hospital
 Universitario de Fuenlabrada,
 Camino del Molino nº 2., 28942 Fuenlabrada,
 Madrid, Spain
 e-mail: ire.9695@hotmail.es

Oncology in Clinical Practice
 DOI: 10.5603/OCP.2023.0026
 Copyright © 2023 Via Medica
 ISSN 2450-1654
 e-ISSN 2450-6478

ABSTRACT

Compared to other breast cancer subtypes, triple-negative breast cancer presents a worse prognosis and higher mortality. Even in localized stages, the risk of relapse is high, especially in patients with \geq cT2 and/or \geq cN1. We know that those patients who achieve a complete pathologic response after neoadjuvant treatment have better disease-free survival. Therefore, many research efforts have been made to try to optimize neoadjuvant chemo/immunotherapy to increase pathologic complete response rates. The available evidence related to that subject matter is summarized in this article. In the field of adjuvant therapy, the challenge of improving disease-free survival in those patients who do not achieve pathologic complete response after neoadjuvant therapy stands out. The second part of this article will deal with the challenges inherent to this issue.

Keywords: adjuvant treatment, disease-free survival, early breast cancer, neoadjuvant treatment, pathological complete response, treatment personalization, triple-negative breast cancer

Oncol Clin Pract 2023; 19, 5: 362-370

Introduction

In the treatment of early-stage triple-negative breast cancer (TNBC), guidelines distinguish between two major therapeutic branches: 1) in those tumors with clinical stage cT1N0, they recommended performing upfront surgery with the possibility of subsequent adjuvant treatment depending on the pathological stage and 2) in those tumors with clinical stage \geq cT2 and/or \geq cN1, they recommend neoadjuvant therapy followed by surgery and subsequent adjuvant treatment [1].

Compared to other subtypes of breast cancer, TNBC has a worse prognosis and higher mortality, even when it debuts in a localized form. We know that those patients who achieve a complete pathologic response after

neoadjuvant therapy have better disease-free survival. Therefore, research efforts have been oriented towards the optimization of neoadjuvant chemo/immunotherapy to increase pathological complete response (pCR) rates without disregarding the issue of toxicity accumulation that can limit successive lines as well as the selection of patient profiles based on biomarkers that determine their risk of relapse to individualize treatment in terms of adoption of escalation and de-escalation strategies.

We also know that patients who do not achieve pCR have lower disease-free survival (DFS: invasive iDFS or distant DDFS) despite the available adjuvant treatments. In the field of adjuvant therapy, the challenge of improving survival parameters in this subgroup of patients and exploring new drugs as well as escalation strategies stands out.

Received: 27.03.2023 Accepted: 07.05.2023 Early publication date: 03.07.2023

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

Optimizing the search for complete pathologic response in neoadjuvant therapy

Nuances in the management of cT1N0 tumors

In tumors with clinical stage cT1N0, the guidelines initially recommend performing surgery. If the pathologic stage is pT1aN0, follow-up is recommended. However, in all patients whose pathological stage results are \geq pT2 and/or \geq pN1 and, generally speaking, also in those with pT1b-c pN0, they recommended performing adjuvant treatment [with chemotherapy (QT) or with targeted therapy (TD) with PARP inhibitors in the case of *BRCA* mutations] [1].

In the case of patients with minimal tumor disease in the pathologic specimen (pT1b-cN0), the question is what parameters are indicative of good prognosis that would allow for individualized management and selection of those patients who may be exempt from the toxicity of adjuvant treatment that can be detrimental to their long-term survival.

The European Society for Medical Oncology (ESMO) 2022 guidelines distinguish four histology types which are associated with good prognosis: apocrine, secretory, medullary, and cystic adenoid. They point out that, within these histology types, follow-up could be considered due to their 5-year overall survival (OS) of more than 92% [1].

However, the frequency of these histologies is low, which has led to the search for other markers that can guide de-escalation, such as the proliferation index (ki67) or tumor-infiltrating lymphocytes (TILs). The prognostic role of TILs is indisputable (level of evidence 1B) and has been demonstrated in several studies [1].

Park et al. [2] reviewed a cohort of 476 patients from 4 centers (1989–2015) with resected TNBC without perioperative QT. Retrospectively, they assessed the percentage of TILs in the surgical specimen, stratifying into two groups: TILs $<$ 30% and TILs \geq 30%. They concluded that stage I TNBC patients with TILs \geq 30% form a subgroup with excellent prognosis without adjuvant chemotherapy [at 5 years: DFS 91% (95% CI 84–96), D-DFS 97% (95% CI 93–100), OS 98% (95% CI 95–100)] [2].

Similarly, De Jong et al. [3] retrospectively reviewed a sample of 441 patients from the German registry (1989–2000), younger than 40 years at diagnosis, with pT1-3N0 and without perioperative chemotherapy. They stratified TILs into three groups: $<$ 30%, 30–75%, and \geq 75%. At 15 years, the cumulative incidence of distant metastases or death was 2.1% for the subgroup with high TILs \geq 75% (95% CI: 0–5) and 38.4% for the subgroup of low TILs $<$ 30%. Furthermore, each 10% increase in TILs correlated with a 19% decrease

in the risk of death [adjusted hazard ratio (HR) = 0.81; 95% CI 0.76–0.87]. They concluded, therefore, that young, QT-naive, N0 TNBC patients with sTILs \geq 75% have an excellent long-term prognosis, and prospective clinical trials investigating (neo)adjuvant QT de-escalation strategies should be considered in this subgroup [3]. Because of the aforementioned lack of prospective clinical trials, there is still no evidence to make therapeutic decisions based solely on this parameter, and, therefore, it is not currently recommended in the clinical practice guidelines. However, this is an emerging line of research that will provide new developments in the coming years.

Triple-negative breast cancer with \geq cT2 and/or \geq cN1: gaining further knowledge of neoadjuvant therapy

For the treatment of TNBC \geq cT2 and/or \geq cN1, the NCCN 2022 guidelines issue multiple recommendations regarding options for therapeutic schemes which they classify under three headings: “preferred regimens”, “regimens useful in certain circumstances” “other recommended regimens” [4].

The NCCN 2022 guidelines lay out fundamental concepts according to which: 1) the recommended schedule with the most evidence is AC $>$ T biweekly or weekly (where “A” indicates doxorubicin, “C”, cyclophosphamide, and “T”, paclitaxel) 2) for high-risk TNBC, the guidelines recommend combining QT with pembrolizumab in neoadjuvant treatment according to the KEYNOTE 522 scheme 3) the combination of carboplatin with paclitaxel/docetaxel is mentioned in the preoperative setting but is not routinely recommended for most patients 4) bevacizumab has no place in (neo)adjuvant therapy and is recommended in combination with chemotherapy only for selected patients with recurrent or stage IV disease [4]. The ESMO 2022 guidelines reinforce the same concepts [1].

Neoadjuvant chemotherapy

Classically, three fundamental questions have been considered around the issue of neoadjuvant chemotherapy in TNBC \geq cT2 and/or \geq cN1: 1) should carboplatin be added? 2) what is the role of bevacizumab? 3) are anthracyclines necessary? We will try to answer them below.

Should carboplatin be added?

There are subgroups within TNBC (such as those associated with *BRCA* mutations), in which the inherent defect in DNA repair based on homologous recombination increases sensitivity to alkylating agents, such as carboplatin [5]. Table 1 [6–12] summarizes the most important characteristics of the main clinical trials related to the study of the addition of carboplatin to neoadjuvant chemotherapy. Several issues are noteworthy:

1. All trials are phase II except the GeparOcto/GBG84 trial [10] and BrighTNess trial [11, 12], which are phase III;
2. There is great variability in the design of the trials, including combinations and sequencing of different chemotherapy agents, with variability in doses. Some also include targeted therapies (veliparib) or antiangiogenics (bevacizumab). The heterogeneity in the design makes the results difficult to compare;
3. The primary endpoint for all of them was pCR, with significant differences in favor of carboplatin use of around 25% in both BrighTNess [11, 12] and ISPY-2 [9] and around 15% in GeparSixto/GBG66 [8] and CALGB 40603 [7];
4. Regarding survival data, it is remarkable that no trial achieved significant differences in OS. In contrast, in GeparSixto/GBG66 [8] and BrighTNess [11, 12], significant differences in DFS in favor of carboplatin were achieved.

Of all the trials mentioned, BrighTNess [11, 12] is noteworthy for its relevance. It is a three-arm phase III trial that randomized women > 18 years, with ECOG 0–1, with

stage II/III TNBC and potential surgical candidates to receive: paclitaxel (first arm), carboplatin (second arm), with the addition of veliparib to the previous combination (third arm), followed by AC and subsequent surgery. It was a positive trial in terms of pCR and DFS (as shown in Tab. 1). Its authors conclude that:

1. adding carboplatin improved pCR, and this, in turn, translated into improved DFS with no impact on OS;
2. the increase in hematologic toxicity with the addition of carboplatin and the consequent delay in treatment did not worsen end-point outcomes;
3. adding veliparib did not impact pCR, DFS, or OS [11, 12].

What is the role of bevacizumab?

The 2022 NCCN and ESMO guidelines do not consider the use of bevacizumab in the (neo)adjuvant setting [1, 4]. This is because although clinical trials of bevacizumab in the neoadjuvant setting are positive for the primary end-point (pCR), this does not translate into a significant increase in DFS/OS [7, 13–15]. Likewise, in the adjuvant setting, the BEATRICE trial also did not

Table 1. Main trials related to the study of carboplatin in combination in neoadjuvant therapy for the treatment of early triple-negative breast cancer

| Trial | Phase | N | Design | pCR [%] | DFS/OS (HR) |
|---------------------------|-------|-----|---|--|---|
| GEICAM 2006/03 [6] | II | 94 | EC × 4 > T ₁₀₀ × 4 T ₇₅ Cb × 4 | 30% vs. 30% | — |
| CALGB 40603 [7] | II | 443 | wP ± Cbq3w > AC × 4 ± Bev | 41% vs. 54% (increase 13%)* | 5 yr DFS: 70.1% vs. 70.4% HR = 0.94 (NS) 5 yr OS: 75.6% vs. 74.4% HR = 1.12 (NS) |
| GeparSixto/ /GBG66 [8] | II | 315 | wP + wN- PLD ± Bev ± wCb | 37% vs. 53% (increase 16%)* | 3 yr DFS: 86.1% vs. 75.8% HR = 0.56* 3 yr OS: 91.9% vs. 86% HR = 0.60 (NS) |
| ISPY-2 [9] | II | 60 | wP ± Cb + V > AC × 4 | 26% vs. 51%* (increase 25%) | — |
| GeparOcto/ /GBG84 [10] | III | 403 | wP NPLD Cb vs. EP q2w × 3 > Cq2w × 3 | 48,5% vs. 51.7% | — |
| BrighTNess [11, 12] | III | 634 | wP ± Cb ± V > AC × 4 | 31% vs. 58% (Cb) vs. 53% (CbV) (increase 26%)* | 4.5 yr DFS: 68.5% vs. 78.2% vs. 79.3% 4.5 yr OS: 86.1% vs. 88% vs. 90% HR = 0.82 (NS) HR = 0.63 (NS) HR = 1.25 (NS) |

*Statistically significant value; > — followed by; A — doxorubicin; Bev — bevacizumab; C — cyclophosphamide; Cb — carboplatin; DFS — disease-free survival; E — epirubicin; HR — hazard ratio; NPLD — non-pegylated liposomal doxorubicin; NS — not significant; OS — overall survival; P — paclitaxel; pCR — pathological complete response; q — dose; T — docetaxel; V — veliparib; w — weekly; yr — year

Table 2. Main trials related to the study of bevacizumab in combination with in neoadjuvant therapy for the treatment of early triple-negative breast cancer

| Trial | Phase | N | Design | pCR [%] | DFS/OS (HR) |
|-----------------------------------|-------|------|-----------------------------|------------------------------------|---|
| In the neoadjuvant setting | | | | | |
| CALGB 40603 [7, 14] | II | 443 | wP ± Cbq3w > AC × 4 ± Beva | 41% vs. 54% (increase 13%)* | 5 yr DFS: 70.1% vs. 70.4% HR = 0.94 (NS) 5 yr OS: 75.6% vs. 74.4% HR = 1.12 (NS) |
| GeparQuinto/ /GBG44 [13] | II | 315 | ECq3w × 4 > Dq3w × 4 ± Beva | 27.9% vs. 39.3% (increase 11%)* | 3 yr DFS: 75.5% vs. 72.9% (NS) 3 yr OS: 85.5% vs. 80.9% (NS) |
| ARTEMIS [15] | III | 800 | T × 3 > CEF × 3 ± Beva | 45% vs. 31% (increase 14%)* | 3.5 yr DFS: 74% vs. 78% HR = 1.18 (NS) 3.5 yr OS: 81% vs. 84% HR = 1.26 (NS) |
| In the adjuvant setting | | | | | |
| BEATRIZ [16] | III | 2591 | AT ± Beva × 4 | — | 3 yr DFS: 82.7% vs. 83.7% HR = 0.87 (NS) |

*Statistically significant value; > — followed by; A — doxorubicin; Bev — bevacizumab; C — cyclophosphamide; Cb — carboplatin; DFS — disease-free survival; E — epirubicin; F — fluorouracil; HR — hazard ratio; NPLD — non-pegylated liposomal doxorubicin; NS — not significant; OS — overall survival; P — paclitaxel; pCR — pathological complete response; q — dose; T — docetaxel; V — veliparib; yr — year

demonstrate a significant increase in survival parameters [16]. The results of the main trials are summarized in Table 2 [7, 13–16].

Are anthracyclines necessary?

Anthracyclines are chemotherapeutics with widely demonstrated efficacy in the treatment of TNBC. However, they carry cardiovascular risks and the risk of secondary leukemias in the long term [5]. Especially in localized stages, where the fundamental curative pillar is surgery, it is advisable to try to reduce as much as possible the toxicity derived from neoadjuvant treatment that may be detrimental, in the long term, to the quality of life of the patients and therapeutic possibilities in successive lines. For this reason, de-escalation trials have been designed to try to evaluate the benefit-toxicity balance that anthracyclines bring to perioperative treatment. Some of them include an anthracycline arm in the design. Others, however, omit them and compare them with the results available in the literature. Table 3 [17–21] lists the main trials in this regard.

None of the trials listed in Table 3 conclude in favor of anthracyclines although only two (the NCT01276769 trial [18] and the NeoCART trial [20]) obtain higher pCR rates with the alternative scheme. The remaining trials highlight the non-inferiority of omitting anthracyclines and the resulting benefits in tolerability. The phase II trial NCT01276769 compared paclitaxel plus carboplatin versus epirubicin plus paclitaxel [18]. It concluded the superiority of carboplatin with a significant difference in terms of pCR and DFS at 4 years [18]. However, it should be remembered that the chemotherapy scheme recommended with the most evidence

in the 2022 NCCN guidelines is anthracycline plus cyclophosphamide followed by taxane [4]. The design of the study NCT01276769 can, therefore, be questioned for not comparing the taxane-platinum combination with the standard combination. The phase II NeoCART trial, on the other hand, was designed to compare the taxane-platinum combination with AC followed by taxane [20]. A significant pCR benefit in favor of carboplatin was maintained, however, no differences in survival parameters were obtained [20].

Conclusions regarding neoadjuvant chemotherapy

Heterogeneity in the study design makes it difficult to draw clear conclusions. In this regard, Li J. et al. [22] designed a meta-analysis comparing different chemotherapy schedules for the treatment of stage I–III TNBC. They included randomized trials with the control group, published in English. From an initial search of more than 2000 references, they finally selected 35 clinical trials. As the primary objective, they compared pCR, and as the secondary objective they compared the aggregate adverse effects (AEs), defined as total adverse effects grade 3 or higher. They concluded that adding platinum to neoadjuvant TNBC treatment, both in regimens in which it is combined with taxanes alone (TCb; OR = 2.16; 95% CI 1.20–3.91) and in those that also include anthracyclines (ATPt; OR = 2.04; 95% CI 1.69–2.48), significantly increases the pCR rate with respect to AT regimens. Furthermore, without anthracyclines, it improves tolerance without worsening the pCR rate, although no significant differences were obtained in the incidence of severe ALE (OR = 0.66; 95% CI 0.23–1.72) [22].

Table 3. Main trials related to the possibility of omitting anthracyclines in neoadjuvant treatment of early triple-negative breast cancer

| Trial | Phase | N | Design | pCR [%] | DFS/OS (HR) |
|--|-------|-----|--|--|--|
| PROGECT (NCT01560663) Compare results with available literature [17] | — | 190 | TCb q3w × 6 | 55% Similar rate to ACb but better safety profile. | 3 yr DFS: 79% 3 yr OS: 87% |
| NCT01276769 [18] | II | 91 | PCb q3w vs. EP q3w × 6 | 14.0% (EP) vs. 38.9% (PCb)* | 4 yr DFS: 52.8% (EP) vs. 71.1% (PCb)*; p = 0.080 4 yr OS: 70.1% vs. 72.5% (NS); p = 0.980 |
| TBCRC030 [19] | II | 139 | wPx12 vs. CDDP q3w × 4 | 11.9% P vs. 15.3% CDDP | — |
| NeoCART [20] | II | 93 | TCb q3wx6 vs. EC × 4 > T × 4 | 61.4% vs. 38.6% * | 3 yr DFS: 88.3% vs. 90.8% (NS); HR = 0.76 3 yr OS: 92.8% vs. 93.1% (NS); HR = 0.96 |
| NeoSTOP [21] | II | 100 | wP ± Cb q3w × 4 > AC × 4 vs. TCb q3w × 6 | 54% vs. 54% | 3 yr DFS and OS: NS between both arms and significantly higher in those achieving pCR regardless of treatment received pCR 3 yr DFS: 100% vs. 81% pCR 3 yr OS: 100% vs. 86% |

*Statistically significant value; > — followed by; A — doxorubicin; Bev — bevacizumab; C — cyclophosphamide; Cb — carboplatin; CDDP — cisplatin; DFS — disease-free survival; E — epirubicin; HR — hazard ratio; NPLD — non-pegylated liposomal doxorubicin; NS — not significant; OS — overall survival; P — paclitaxel; pCR — pathological complete response; q — dose; T — docetaxel; V — veliparib; w — weekly; yr — year

Neoadjuvant immunotherapy

Figure 1 [23–28] summarizes the current immunotherapy (IT) landscape for neoadjuvant treatment in early-stage TNBC. Atezolizumab gained FDA approval in 2019 and EMA approval in 2020 in combination with paclitaxel-albumin based on the results of the IMPASSION 031 trial [22]. Pembrolizumab was approved in 2021 by the FDA in combination with chemotherapy as neoadjuvant treatment and in adjuvant monotherapy based on the results of the KEYNOTE 522 trial [24, 25]. The EMA also approved it in 2021 but only for CPS ≥ 10, rectifying the approval in 2022 when it became approved regardless of PDL1 levels. Nivolumab is not tested in early stages, but the phase II TONIC trial was designed for metastatic TNBC [28, 29].

The IMPASSION 031 phase III clinical trial randomized patients with cT2–T4 cN0–N3 cM0 TNBC who had not received prior treatment to receive paclitaxel albumin ± atezolizumab followed by anthracycline + cyclophosphamide ± atezolizumab in the neoadjuvant phase. After surgery, those patients in the IT arm continued with atezolizumab in adjuvant versus placebo in the control arm. It was a positive trial in favor of using atezolizumab in terms of its primary end-point, significantly improving pCR both in the overall sample and when stratifying by PD-L1 (overall: 57.6% vs. 41.1%; Δ16.5%; 95% CI 5.9–27.1; PD-L1 positive: 68.8% vs. 49.3%, Δ19.5%; 95% CI 4.2–39.8; PD-L1 negative: 47.7% vs. 34.4%, Δ13.3%; 95% CI from –0.9 to 27.5). No significant differences were found in survival parameters [23].

The NeoTRIP phase III clinical trial was, in contrast, a pCR-negative trial at its primary endpoint. It randomized patients with previously untreated early-stage TNBC to receive carboplatin + taxane ± atezolizumab. After surgery, adjuvant treatment was performed in both arms with QT (AC/EP/FEC). They concluded that adding atezolizumab to the nab-paclitaxel + carboplatin scheme did not significantly increase the pCR rate [24].

The phase III GEPAR-DUOZE trial is still ongoing. Its design randomizes patients with early TNBC to receive carboplatin + taxane ± atezolizumab followed by epirubicin + cyclophosphamide ± atezolizumab. After surgery, adjuvant will be performed with atezolizumab for the IT arm versus placebo [25].

The phase III KEYNOTE 522 trial, in addition to achieving FDA and EMA approval of pembrolizumab in combination with QT for the perioperative treatment of early TNBC, positioned the scheme at ESMO 2021 as the new standard of care. Patients were randomized to receive carboplatin + taxol ± pembrolizumab sequenced with anthracycline + cyclophosphamide. After surgery, the IT arm maintained pembrolizumab in adjuvant vs. placebo in the control arm. The study concluded in favor of using pembrolizumab in (neo) adjuvant, with a significant increase in pCR rate (66.8% vs. 51.2%; p = 0.00055) as well as DFS at 36 months (84.5% vs. 76.8%; HR = 0.63; 95% CI 0.43–0.82). The benefit was maintained in all subgroups, being independent of PD-L1 [26, 27].

The results in DFS stratified by pCR of KEYNOTE 522 are interesting. Those patients who achieve




| | | | |
|--|-------------------------------------|--|---|
|  Atezolizumab | IMPASSION 031 Ref. [23] | PHASE III n = 333 | Atezo + Nab-P > Atezo + AC Adjuvant immunotherapy |
| | NeoTRIP Ref. [24] | PHASE III n = 280 | Atezo + Nab-P + Cb Adjuvant chemotherapy |
| | GEPAR-DUOZE NCT03281954 | PHASE III Currently ongoing | Atezo + P + Cb > Atezo + EC Adjuvant immunotherapy |
|  Pembrolizumab | KEYNOTE 522 Ref. [25, 26] | PHASE III n = 1174 | Pembro + P + Cb × 4 > AC/EC × 4 Adjuvant immunotherapy |
| | I-SPY2 Ref. [27] | PHASE II/III n = TN29/180 | P ± Pembro > AC No adjuvant |
|  Durvalumab | GeparNuevo Ref. [28] | PHASE II n = 174 | Durva > Nab-P + Durva > EC + Durva No adjuvant |

Figure 1. Overview of the main clinical trials on the use of IT in the neoadjuvant treatment of early-stage triple-negative breast cancer [Based on: slide N°37 SEOM VIRTUAL 2020 “CM TN: Immunotherapy is here to stay” Dr. Elena García-Martínez. Morales Meseguer University Hospital. Murcia]; > — followed by; A — doxorubicin; Atezo — atezolizumab; C — cyclophosphamide; Cb — carboplatin; Durva — durvalumab; E — epirubicin; P — paclitaxel; Pembro — pembrolizumab; T — docetaxel

pCR, regardless of how they achieve it, maintain high DFS 36 months, around 93% (DFS 36 months pCR IT arm 94.4%, DFS 36 months pCR QT arm 92.5%, with no significant difference HR = 0.73; 95% CI 0.39–1.36). However, for those who do not achieve pCR, there is a clear benefit in favor of the use of pembrolizumab (at 36 months, DFS IT vs. QT arm 67.4% vs. 56.8%; HR = 0.70 95% CI 0.52–0.95). Despite this, it is noteworthy that there continues to be a difference of around 30% in DFS at 36 months between those patients who receive IT and achieve pCR and those who do not. This concept will be important in thinking about the question of adjuvant [26, 27].

The KEYNOTE 522 trial reported no significant difference in terms of OS at 36 months (89.7% vs. 86.9%; HR = 0.72; 95% CI 0.51–1.02) [26, 27].

The phase II/III I-SPY2 trial is still ongoing. It has an adaptive design that allows the inclusion of new research arms that are compared in parallel. It is designed for high-risk stage II/III breast tumors, with an interim analysis published on the use of pembrolizumab. Data on 250 patients were analyzed, of which 69 were included in the pembrolizumab arm, with only 20 TNBC. In patients with TNBC, there was a significant increase in the pCR rate (60% vs. 12%) in favor of pembrolizumab. Consistent with the results of the KEYNOTE 522 trial,

in those patients who did not obtain pCR, the fact of having received pembrolizumab in neoadjuvant therapy improved their DFS with respect to the control [28].

In phase II GeparNuevo trial, which evaluated the combination of durvalumab with QT, was negative in terms of its primary end-point pCR (53.4% vs. 44.2%; $p = 0.28$). However, it is striking that the reported results regarding 3-year survival parameters were all significantly favorable to the durvalumab arm [iDFS 77.2% vs. 85.6% (HR = 0.48; 95% CI 0.27–1.09), DDFS 78.4% vs. 91.7% (HR = 0.31; 95% CI 0.13–0.74) OS 83.5% vs. 95.2% (HR = 0.24; 95% CI 0.08–0.72)] [29].

Issues and challenges in sequential adjuvant

cT2 and/or \geq cN1: the question of adjuvant after neoadjuvant

Figure 2 [26, 27, 30, 31] summarizes adjuvant options after neoadjuvant and surgery in early-stage TNBC.

In patients who achieve pCR

A good starting point to address the question of adjuvant after neoadjuvant treatment in TNBC is to return




Figure 2. Overview of adjuvant options after neoadjuvant and surgery in early-stage triple-negative breast cancer; pCR — pathological complete response

to the results in pCR-stratified DFS of the KEYNOTE 522 trial, which reinforced the favorable prognosis of patients who achieve pCR, regardless of the treatment with which they achieve it [26, 27].

Within this subgroup of patients, there is the possibility of continuing with pembrolizumab in adjuvant (after performing neoadjuvant with pembrolizumab) based on the KEYNOTE-522 scheme [26, 27].

However, the results of stratification of survival curves by pCR suggest that de-escalation approaches could be explored with a clear clinical impact in terms of toxicity [32, 33]. The OptimICE-PCR trial is designed to randomize patients with TNBC and pCR after neoadjuvant chemioimmunotherapy to adjuvant pembrolizumab for 27 weeks or observation. There are no published results yet [34].

In patients who do not achieve pCR

Given the significant benefit in DFS relative to the use of IT with pembrolizumab according to the KEYNOTE 522 scheme, in those patients who do not achieve pCR it could be concluded that, without a doubt, this subgroup of patients who receive IT in neoadjuvant therapy should continue with pembrolizumab in adjuvant therapy [26, 27]. However, there are several caveats to this categorical statement.

First, the KEYNOTE 522 trial confronted pembrolizumab versus placebo in adjuvant, without including capecitabine in adjuvant as a control group. This is because recruitment for this study began before this drug was positioned in adjuvant as standard of care, following the results of the CREATE-X trial [32, 33]. In the phase III CREATE-X trial capecitabine demonstrated benefit in DFS and OS at 5 years versus placebo (DFS 74.1%

vs. 67.7%; HR = 0.7; p = 0.005; OS 89.2% vs. 83.9%; p < 0.01) [30].

Second, despite continuing with pembrolizumab, DFS remains approximately 30% lower relative to those patients achieving pCR. Bonadio et al. [33] reflected on this point in their article on management of TNBC patients after neoadjuvant pembrolizumab. They pointed out the importance of exploring escalation strategies, such as the possibility of administering concomitant pembrolizumab + capecitabine or designing adjuvant strategies with sequence therapy [33].

In addition, among patients who do not achieve pCR, there is a subgroup with a worse prognosis. Within KEYNOTE-522, a subanalysis of outcomes stratified by residual cancer burden (RCB) was performed. It was observed that patients with higher residual disease burden (defined as RCB-3) had worse survival rates, and it was striking that this subgroup of patients had worse DFS at 3 years in the IT arm compared to the control (DFS 26.2% pembrolizumab; 95% CI 13.5–41 vs. 34.6% control; 95% CI 17.5–52.5). In this subgroup, it is urgent to explore escalation strategies [33]. In our center, we tried to include these patients with particularly poor prognoses in a clinical trial.

Third, at the San Antonio Breast Cancer Symposium 2022, a post-hoc analysis exploring the role of adjuvant radiotherapy in the results of the KEYNOTE-522 trial was published as a poster. They classified patients according to whether or not they had received adjuvant radiotherapy and, in those who had received it, distinguished according to whether it was administered concurrently or sequentially. The pCR rate was determined

as the primary endpoint and survival and toxicity data as secondary endpoints. In this post-hoc analysis, the administration of adjuvant RT and how it was administered did not influence the results with respect to pCR and DFS [35].

Fourth, targeted therapy with PARP inhibitors is another possibility in the adjuvant treatment of patients with TNBC and mutated *BRCA*. This mutation is present in about 10–15% of TNBC patients [33]. The phase III OlympiA clinical trial led to the approval of olaparib in an adjuvant setting. They included patients with germline *BRCA1/2* mutation who had received prior perioperative chemotherapy with anthracycline (and/or taxane) based regimens and stratified them into two subgroups: patients with TN tumors on the one hand and patients with HER2-positive/hormone receptor-positive tumors on the other. Within both groups, patients were randomized to receive olaparib versus placebo. The primary endpoint was iDFS, with a statistically significant difference in favor of olaparib at 36 months (85.9% vs. 77.1%; HR = 0.58; 95% CI 0.41–0.82), with benefit maintained in all subgroups. It also concluded in favor of olaparib in terms of DDFS at 36 months (87.5% vs. 80.4%; HR = 0.57; 95% CI 0.39–0.83). However, no significant difference was found in OS (92% vs. 88.3%; HR = 0.68; 95% CI 0.44–1.05) [31].

Bonadio et al. [33] recommend prioritizing olaparib as adjuvant therapy for BRCA-mutated tumors. They point out that, although there are no studies directly comparing olaparib with capecitabine or pembrolizumab, in the case of ovarian cancer (in which the prevalence of *BRCA1/2* germline mutations and homologous recombination deficiency are higher), clinical trials have shown little activity of immunotherapy in monotherapy. By extrapolation, given the pathophysiologic similarity, these authors are betting on olaparib in this particular clinical scenario [33].

Fifth, we should not forget the possibility of including our patients in clinical trials, especially if we can predict, based on the available evidence, a worse prognosis with the treatments approved to date.

Within the broad landscape of clinical trials, the ongoing phase III SASCIA trial is noteworthy. It is designed to compare adjuvant sacitumumab-govitecan versus the treating physician's adjuvant treatment of choice. Although they support other patient profiles, patients with TNBC who have not achieved pCR after 16 weeks of neoadjuvant taxane-based QT can be included in this trial [36].

Conclusions

The search for pCR in neoadjuvant therapy and the issues and challenges in sequential adjuvant therapy in localized stages of TNBC are currently two hot topics.

In neoadjuvant, efforts have been directed to optimize the chemotherapy schedule, with the role of platinum-based drugs gaining relevance and the role of anthracyclines being increasingly questioned in relation to their inherent toxicity. The combination with immunotherapy (pembrolizumab) has revolutionized the therapeutic landscape and is currently considered the new standard of care for high-risk patients.

Research on adjuvant therapy after neoadjuvant therapy is at its peak, with numerous investigations open in this field. Although we have tools such as capecitabine, pembrolizumab (in the case of having received neoadjuvant therapy with IT), or olaparib (in the case of germline BRCA-mutated tumors), there is an urgent need to design escalation strategies and investigate new drugs that improve DFS in those patients who do not achieve pCR after neoadjuvant therapy.

Article Information and Declarations

Author contributions

I.S.L.: conceptualization, visualization, methodology, project management, writing; proofreading and editing. J.A.G.M.: proofreading and editing. D.M.G., L.R.L., C.P.G., A.M.M.F. de S., C. de Z. L., B.L.V., N.S.B., F.E.M., E.M.M., D.G.A., I.J.M., B.J.M., B.J.M., J.C.R.: editing.

Funding

None.

Acknowledgments

None.

Conflict of interest

The authors declare no conflicts of interest.

References

- Cardoso F, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol*. 2019; 30(8): 1194–1220, doi: [10.1093/annonc/mdz173](https://doi.org/10.1093/annonc/mdz173), indexed in Pubmed: [31161190](https://pubmed.ncbi.nlm.nih.gov/31161190/).
- Park JH, Jonas SF, Bataillon G, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Ann Oncol*. 2019; 30(12): 1941–1949, doi: [10.1093/annonc/mdz395](https://doi.org/10.1093/annonc/mdz395), indexed in Pubmed: [31566659](https://pubmed.ncbi.nlm.nih.gov/31566659/).
- de Jong VMT, Wang Y, Ter Hoeve ND, et al. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. *J Clin Oncol*. 2022; 40(21): 2361–2374, doi: [10.1200/JCO.21.01536](https://doi.org/10.1200/JCO.21.01536), indexed in Pubmed: [35353548](https://pubmed.ncbi.nlm.nih.gov/35353548/).
- NCCN Clinical Practice Guidelines in Oncology (NCCN. Guidelines). Versión 4.2022 (internet). Breast Cancer.
- McAndrew N, DeMichele A. Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer. *J Target Ther Cancer*. 2018; 7(1): 52–69, indexed in Pubmed: [29577076](https://pubmed.ncbi.nlm.nih.gov/29577076/).

6. Alba E, Calvo L, Albanell J, et al. GEICAM. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. *Ann Oncol*. 2012; 23(12): 3069–3074, doi: [10.1093/annonc/mds132](https://doi.org/10.1093/annonc/mds132), indexed in Pubmed: [22674146](https://pubmed.ncbi.nlm.nih.gov/22674146/).
7. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). *J Clin Oncol*. 2015; 33(1): 13–21, doi: [10.1200/JCO.2014.57.0572](https://doi.org/10.1200/JCO.2014.57.0572), indexed in Pubmed: [25092775](https://pubmed.ncbi.nlm.nih.gov/25092775/).
8. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol*. 2014; 15(7): 747–756, doi: [10.1016/S1470-2045\(14\)70160-3](https://doi.org/10.1016/S1470-2045(14)70160-3), indexed in Pubmed: [24794243](https://pubmed.ncbi.nlm.nih.gov/24794243/).
9. Wang H, Yee D. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. *Curr Breast Cancer Rep*. 2019; 11(4): 303–310, doi: [10.1007/s12609-019-00334-2](https://doi.org/10.1007/s12609-019-00334-2), indexed in Pubmed: [33312344](https://pubmed.ncbi.nlm.nih.gov/33312344/).
10. Schneeweiss A, Möbus V, Tesch H, et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. *Eur J Cancer*. 2019; 106: 181–192, doi: [10.1016/j.ejca.2018.10.015](https://doi.org/10.1016/j.ejca.2018.10.015), indexed in Pubmed: [30528802](https://pubmed.ncbi.nlm.nih.gov/30528802/).
11. Geyer C, O'Shaughnessy J, Untch M, et al. Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). *J Clin Oncol*. 2017; 35(15_suppl): 520–520, doi: [10.1200/jco.2017.35.15_suppl.520](https://doi.org/10.1200/jco.2017.35.15_suppl.520).
12. Geyer CE, Sikov WM, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrightNess, a randomized phase III trial. *Ann Oncol*. 2022; 33(4): 384–394, doi: [10.1016/j.annonc.2022.01.009](https://doi.org/10.1016/j.annonc.2022.01.009), indexed in Pubmed: [35093516](https://pubmed.ncbi.nlm.nih.gov/35093516/).
13. Gerber B, Loibl S, Eidtmann H, et al. German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the gearquinto study (GBG 44). *Ann Oncol*. 2013; 24(12): 2978–2984, doi: [10.1093/annonc/mdt361](https://doi.org/10.1093/annonc/mdt361), indexed in Pubmed: [24136883](https://pubmed.ncbi.nlm.nih.gov/24136883/).
14. Sikov WM, Berry DA, Perou CM, et al. Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). *Cancer Research*. 2016; 76(4_Supplement): S2-05-S2-05, doi: [10.1158/1538-7445.sabcs15-s2-05](https://doi.org/10.1158/1538-7445.sabcs15-s2-05).
15. Earli H, Hiller L, Dunn J, et al. Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial. *J Clin Oncol*. 2016; 34(15_suppl): 1014–1014, doi: [10.1200/jco.2016.34.15_suppl.1014](https://doi.org/10.1200/jco.2016.34.15_suppl.1014).
16. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. *Lancet Oncol*. 2013; 14(10): 933–942, doi: [10.1016/S1470-2045\(13\)70335-8](https://doi.org/10.1016/S1470-2045(13)70335-8), indexed in Pubmed: [23932548](https://pubmed.ncbi.nlm.nih.gov/23932548/).
17. Sharma P, López-Tarruella S, García-Saenz JA, et al. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. *Clin Cancer Res*. 2017; 23(3): 649–657, doi: [10.1158/1078-0432.CCR-16-0162](https://doi.org/10.1158/1078-0432.CCR-16-0162), indexed in Pubmed: [27301700](https://pubmed.ncbi.nlm.nih.gov/27301700/).
18. Zhang P, Yin Y, Xu B, et al. Abstract P3-14-07: Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer - A phase II clinical trial. *Cancer Research*. 2013; 73(24_Supplement): P3-14-07-P3-14-07, doi: [10.1158/0008-5472.sabcs13-p3-14-07](https://doi.org/10.1158/0008-5472.sabcs13-p3-14-07).
19. Mayer EL, Abramson V, Jankowitz R, et al. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. *Ann Oncol*. 2020; 31(11): 1518–1525, doi: [10.1016/j.annonc.2020.08.2064](https://doi.org/10.1016/j.annonc.2020.08.2064), indexed in Pubmed: [32798689](https://pubmed.ncbi.nlm.nih.gov/32798689/).
20. Zhang L, Wu ZY, Li J, et al. Neoadjuvant docetaxel plus carboplatin vs. epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial. *Int J Cancer*. 2022; 150(4): 654–662, doi: [10.1002/ijc.33830](https://doi.org/10.1002/ijc.33830), indexed in Pubmed: [34591977](https://pubmed.ncbi.nlm.nih.gov/34591977/).
21. Sharma P, Kimler BF, O'Dea A, et al. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP). *Clin Cancer Res*. 2021; 27(4): 975–982, doi: [10.1158/1078-0432.CCR-20-3646](https://doi.org/10.1158/1078-0432.CCR-20-3646), indexed in Pubmed: [33208340](https://pubmed.ncbi.nlm.nih.gov/33208340/).
22. Li J, Chen Li, Tan W, et al. Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis. *Cancer Biol Med*. 2022 [Epub ahead of print]; 19(5): 742–754, doi: [10.20892/j.issn.2095-3941.2021.0529](https://doi.org/10.20892/j.issn.2095-3941.2021.0529), indexed in Pubmed: [35170879](https://pubmed.ncbi.nlm.nih.gov/35170879/).
23. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. *Lancet*. 2020; 396(10257): 1090–1100, doi: [10.1016/S0140-6736\(20\)31953-X](https://doi.org/10.1016/S0140-6736(20)31953-X), indexed in Pubmed: [32966830](https://pubmed.ncbi.nlm.nih.gov/32966830/).
24. Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelan-gelo randomized study. *Ann Oncol*. 2022; 33(5): 534–543, doi: [10.1016/j.annonc.2022.02.004](https://doi.org/10.1016/j.annonc.2022.02.004), indexed in Pubmed: [35182721](https://pubmed.ncbi.nlm.nih.gov/35182721/).
25. Geyer C, Loibl S, Rastogi P, et al. NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. *J Clin Oncol*. 2018; 36(15_suppl): TPS603–TPS603, doi: [10.1200/jco.2018.36.15_suppl.tps603](https://doi.org/10.1200/jco.2018.36.15_suppl.tps603).
26. Schmid P, Cortes J, Pusztai L, et al. KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med*. 2020; 382(9): 810–821, doi: [10.1056/NEJMoa1910549](https://doi.org/10.1056/NEJMoa1910549), indexed in Pubmed: [32101663](https://pubmed.ncbi.nlm.nih.gov/32101663/).
27. Schmid P, Cortes J, Dent R, et al. KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. *N Engl J Med*. 2022; 386(6): 556–567, doi: [10.1056/NEJMoa2112651](https://doi.org/10.1056/NEJMoa2112651), indexed in Pubmed: [35139274](https://pubmed.ncbi.nlm.nih.gov/35139274/).
28. Nanda R, Liu MC, Yau C, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. *JAMA Oncol*. 2020; 6(5): 676–684, doi: [10.1001/jamaoncol.2019.6650](https://doi.org/10.1001/jamaoncol.2019.6650), indexed in Pubmed: [32053137](https://pubmed.ncbi.nlm.nih.gov/32053137/).
29. Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. *Ann Oncol*. 2019; 30(8): 1279–1288, doi: [10.1093/annonc/mdz158](https://doi.org/10.1093/annonc/mdz158), indexed in Pubmed: [31095287](https://pubmed.ncbi.nlm.nih.gov/31095287/).
30. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. *N Engl J Med*. 2017; 376(22): 2147–2159, doi: [10.1056/NEJMoa1612645](https://doi.org/10.1056/NEJMoa1612645), indexed in Pubmed: [28564564](https://pubmed.ncbi.nlm.nih.gov/28564564/).
31. Geyer CE, Garber JE, Gelber RD, et al. OlympiA Clinical Trial Steering Committee and Investigators, OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer. *N Engl J Med*. 2021; 384(25): 2394–2405, doi: [10.1056/NEJ-Moa2105215](https://doi.org/10.1056/NEJ-Moa2105215), indexed in Pubmed: [34081848](https://pubmed.ncbi.nlm.nih.gov/34081848/).
32. Voorwerk L, Slagter M, Horlings HM, et al. Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. *Nat Med*. 2019; 25(7): 1175, doi: [10.1038/s41591-019-0520-5](https://doi.org/10.1038/s41591-019-0520-5), indexed in Pubmed: [31209337](https://pubmed.ncbi.nlm.nih.gov/31209337/).
33. Bonadio RC, Tarantino P, Testa L, et al. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences? *Cancer Treat Rev*. 2022; 110: 102459, doi: [10.1016/j.ctrv.2022.102459](https://doi.org/10.1016/j.ctrv.2022.102459), indexed in Pubmed: [35998514](https://pubmed.ncbi.nlm.nih.gov/35998514/).
34. Elizabeth A. Mittendorf, (2022). Implications of the KEYNOTE-522 Trial for Patients with Early Stage Triple-Negative Breast Cancer. ACS Cancer Research Program. <https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/may-2022-volume-107-number-5/acs-cancer-research-program-implications-of-the-keynote-522-trial-for-patients-with-early-stage-triple-negative-breast-cancer/>.
35. McArthur H, Cortés J, Dent R, et al. Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy followed by adjuvant pembrolizumab vs. placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study. *Cancer Research*. 2023; 83(5_Supplement): PD3-01-PD3-01, doi: [10.1158/1538-7445.sabcs22-pd3-01](https://doi.org/10.1158/1538-7445.sabcs22-pd3-01).
36. Marmé F, Stickeler E, Furlanetto J, et al. Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. *J Clin Oncol*. 2021; 39(15_suppl): TPS602–TPS602, doi: [10.1200/jco.2021.39.15_suppl.tps602](https://doi.org/10.1200/jco.2021.39.15_suppl.tps602).